Comparative Pharmacology
Head-to-head clinical analysis: REDEMPLO versus SHEUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: REDEMPLO versus SHEUR.
REDEMPLO vs SHEUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
REDEMPLO is a synthetic tricyclic analog that acts as a selective serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI). It binds to the presynaptic transporters for serotonin (SERT), norepinephrine (NET), and dopamine (DAT), inhibiting their reuptake and increasing synaptic concentrations of these monoamines. Additionally, it has weak antagonistic properties at the 5-HT2A and alpha-2 adrenergic receptors, contributing to its antidepressant and anxiolytic effects.
SHEUR is a small molecule inhibitor of the bromodomain and extraterminal (BET) family proteins, specifically BRD2, BRD3, BRD4, and BRDT. By binding to acetyl-lysine recognition motifs, it disrupts chromatin remodeling and transcriptional regulation, leading to reduced expression of oncogenes such as MYC.
100 mg orally once daily, with or without food.
No standard dosing available; SHEUR is not a recognized pharmaceutical agent.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged in hepatic impairment (up to 30 hours) and end-stage renal disease (up to 40 hours).
Terminal elimination half-life: 4.5 hours; clinically, steady-state reached within 24 hours.
Primarily hepatic metabolism with 70% renal excretion of metabolites and 30% fecal elimination; less than 5% excreted unchanged in urine.
Renal: 70% unchanged; Biliary/Fecal: 30% as metabolites.
Category C
Category C
Unknown
Unknown